Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VLX103 in Moderate Alcoholic Steatohepatitis
NCT03201159Phase 1Withdrawn
- Start
- Jun 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pentamidine in alcoholic steatohepatitis (ASH) (3 arms). Primary endpoints: Frequencies of subjects experiencing at least one adverse event at 90 days and Distribution of laboratory measures over time at 90 days. Planned start Jun 2017; status: withdrawn.
02
Drugs
pentamidine
03
Conditions
alcoholic steatohepatitis (ASH)
Beyond the preview
Go deeper on NCT03201159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03201159.